- Type 1: Quantitative disease
- dDAVP trial
- Type 2: Qualitative disease
- dDAVP trial; unlikely to be effective
- Type 3: Autosomal recessive d/o with virtually undetectable levels vWF
- Acquired vWF deficiency
- Trial of dDAVP, if not responding, use vWF concentrate or cryprecipitate if emergency
- If antibody mediated acquired vWF deficiency, use IVIG
- Minor bleeding/Minor surgery
- dDAVP, follow bleeding clinically
- If continues to bleed, use vWF concentrate or cryprecipitate if emergency
- Major bleeding/Major surgery
- Recommended to use vWF concentrate or cryprecipitate if emergency
- Continue for 7-14 days, less if sites of bleeding easily monitored and are controlled
Other References
- Keys to the Cart: April 9, 2018; a 5-minute video review of ABA Keywords Link
Copyright Information
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
